Login to Your Account



Clinic Roundup


Tuesday, January 15, 2013
• Reviva Pharmaceuticals Inc., of San Jose, Calif., said it completed patient enrollment in its Phase II study of RP5063 in schizophrenia and schizoaffective disorder. The trial enrolled a total of 234 patients, with top-line data expected by the end of February.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription